peterschreiber.media
Guggenheim has initiated coverage of Metsera (NASDAQ:MTSR) with a buy rating, citing the company’s obesity drug candidates.
The bank highlighted Metsera’s (NASDAQ:MTSR) long-acting GLP-1RA asset MET-097i, saying it was “poised to secure MTSR a stake in the growing obesity market.”
